StockData
Chemomab Therapeutics Ltd. logo

Chemomab Therapeutics Ltd. (CMMB) shareholders

CMMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 5/30
$1.64+0.02 (+1.23%)

Close on Nov 17, 2026Market cap $11.80MP/E 1.1Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
0.1%
0M of 575M shares
Institutional holders
13
1 new, 3 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
2 buys · 2 sales
Net bought $13.73K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
HBM Healthcare Investments (Cayman) Ltd.80,971,68012.50%13D (active) amendmentSep 7, 2026
Scipher Medicine Corp74,576,24010.40%13D (active)Nov 3, 2026
Morgan Stanley
Joint filing with Morgan Stanley & Co. LLC (7.50%)
32,282,6808.40%13G (passive)Jun 30, 2025
Touchstone Global Investments Pty Ltd377,8145.20%13G (passive)Aug 7, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of CMMBValueChange% of portfolio
Citadel Advisors LLC95,3110.02%$154.40K+31,1290.00%
ADAR1 Capital Management, LLC80,0000.01%$129.60K–0.01%
Kestra Private Wealth Services, LLC61,7100.01%$99.97K–0.00%
Ikarian Capital, LLC51,7930.01%$83.90K–0.01%
Rhumbline Advisers30,5290.01%$49.46K+12,1630.00%
XTX Topco Ltd15,9870.00%$25.90K−2,6420.00%
Philadelphia Investment Partners, LLC15,0000.00%$24.30K+6,8000.02%
Lido Advisors, LLC14,3410.00%$23.23KNew0.00%
Bnp Paribas Arbitrage, Snc6,8050.00%$11.02K−1,6200.00%
GAMMA Investing LLC4,7400.00%$7.68K−2,8390.00%
Morgan Stanley3,5750.00%$5.79K−1,0000.00%
SBI Securities Co., Ltd.340.00%$55+60.00%
Caitong International Asset Management Co., Ltd80.00%$13–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026130M0.1%1 / 44 / 30M0M
Q1 2026150M0.1%4 / 63 / 30M0M
Q4 2025140M0.1%6 / 43 / 20M0M
Q3 2025100M0.1%1 / 26 / 50M1M
Q2 2025141M0.2%2 / 53 / 50M0M
Q1 2025171M0.2%1 / 83 / 00M0M
Q4 2024161M0.2%5 / 16 / 40M0M
Q3 2024151M0.2%5 / 42 / 221M1M
Q2 2024332M0.3%3 / 127 / 70M0M
Q1 2024372M0.3%5 / 611 / 30M0M
Q4 2023352M0.3%8 / 610 / 30M0M
Q3 2023302M0.3%4 / 79 / 100M1M

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
George Adi MorChief Executive Officer, Director68,8090.01%Jun 1, 2026
Sigal FatalChief Financial Officer12,5000.00%Apr 10, 2026
John LawlerChief Development Officer10,1480.00%Apr 10, 2026
Neil Harris CohenDirector33,0000.01%Sep 1, 2026
Gwen A. MelincoffDirector––Jun 3, 2026
Alan Charles MosesDirector––Apr 10, 2026
Nissim DarvishDirector3000.00%Apr 10, 2026
Claude NicaiseDirector––Mar 31, 2026
Jill M. QuigleyDirector––Mar 31, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Neil Harris Cohen
Director
Aug 28, 2026Sale−1,000$2.80$2.80K33,000
Neil Harris Cohen
Director
Aug 27, 2026Sale−1,304$2.85$3.72K34,000
George Adi Mor
Chief Executive Officer, Director
May 29, 2026Other−18,750––18,750
George Adi Mor
Chief Executive Officer, Director
May 29, 2026Other−31,712––31,712
George Adi Mor
Chief Executive Officer, Director
May 29, 2026Buy−4,926$2.08$10.25K139,131
George Adi Mor
Chief Executive Officer, Director
May 29, 2026Buy−4,878$2.05$10.00K134,205
Israel BioFund GP Limited Partnership OrbiMed
10% owner
Jan 3, 2023Sale−266,376$3.34$889.70K2,311,798
Israel BioFund GP Limited Partnership OrbiMed
10% owner
Jan 3, 2023Sale−70,524$4.51$318.06K2,241,274
George Adi Mor
Chief Scientific Officer, Director
Jan 3, 2023Sale(10b5-1 plan)−7,700$5.03$38.73K317,075
George Adi Mor
Chief Scientific Officer, Director
Jan 3, 2023Sale(10b5-1 plan)−6,100$5.03$30.68K251,147
Neil Harris Cohen
Director
Nov 16, 2022Sale−2,409$2.00$4.82K10,000
George Adi Mor
Chief Scientific Officer, Director
Nov 16, 2022Sale−257,248$2.08$535.08K257,247
George Adi Mor
Chief Scientific Officer, Director
Nov 16, 2022Sale−324,775$2.08$675.53K324,775
Joel Michael Maryles
Director
May 24, 2022Buy+33$2.76$911,433
Joel Michael Maryles
Director
May 24, 2022Buy+400$2.89$1.16K1,400
Neil Harris Cohen
Director
May 18, 2022Buy+2,000$3.19$6.38K12,409
Joel Michael Maryles
Director
Mar 18, 2022Buy+500$4.32$2.16K500
Joel Michael Maryles
Director
Mar 18, 2022Buy+500$4.36$2.18K1,000
Donald Marvin
Executive VP, CFO & COO
Mar 16, 2022Buy+250$3.25$8132,000
Donald Marvin
Executive VP, CFO & COO
Mar 16, 2022Buy+250$3.30$8251,750
Donald Marvin
Executive VP, CFO & COO
Mar 14, 2022Buy+250$3.98$995500
Donald Marvin
Executive VP, CFO & COO
Mar 14, 2022Buy+250$4.00$1.00K250
Donald Marvin
Executive VP, CFO & COO
Mar 14, 2022Buy+250$4.20$1.05K1,500
Donald Marvin
Executive VP, CFO & COO
Mar 14, 2022Buy+250$4.10$1.03K1,250
Donald Marvin
Executive VP, CFO & COO
Mar 14, 2022Buy+250$3.90$9751,000
Neil Harris Cohen
Director
Mar 14, 2022Buy+2,000$4.20$8.40K6,409
Neil Harris Cohen
Director
Mar 14, 2022Buy+2,000$4.30$8.60K8,409
Neil Harris Cohen
Director
Mar 14, 2022Buy+2,000$4.56$9.12K10,409
Dale R. Pfost
Chief Executive Officer, Director
Mar 14, 2022Buy+1,800$3.98$7.16K1,800
Dale R. Pfost
Chief Executive Officer, Director
Mar 14, 2022Buy+700$3.97$2.78K2,500
Nissim Darvish
Director
Mar 11, 2022Buy+1,200$4.28$5.14K1,200
Neil Harris Cohen
Director
Dec 6, 2021Buy+2,000$7.43$14.86K4,409
Neil Harris Cohen
Director
Mar 16, 2021Buy+2,409$41.51$100.00K2,409
Peter Thiel
10% owner
Mar 16, 2021Buy+230,536––1,108,509
Israel GP Ltd. OrbiMed
10% owner
Mar 16, 2021Award+288,170$17.35$5.00M2,578,174

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
-63.0%
From 0M shares
Short volume, 20 days
24.7%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Chemomab Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 14,542 shares on Aug 28, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
OrbiMed Israel Partners Limited Partnership
Owner
Sep 12, 2024500,000$1.02MSep 12, 2024Merger

See a number that looks wrong?